Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Immunotherapy

Tumour Site

Presenters

Chloe Huang

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

C. Huang1, Y. Chen2, X. Gao3, Y. Li1, J. Lin2, L.Z. Chen2, L.P. Chang3, G. Chen4, Y.F. Guan3, L.K. Pan5, X.F. Xia3, Z.Q. Guo2, J.J. Pan1, X. Yi3, C.B. Chen1

Author affiliations

  • 1 Department Of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Medical University Cancer Hospital, 300014 - Fuzhou/CN
  • 2 Department Of Medical Oncology, Fujian Medical University Cancer Hospital, 350000 - Fuzhou/CN
  • 3 Geneplus-beijing Institute, Geneplus-Beijing Institute, Beijing, China, 102200 - Beijing/CN
  • 4 Pathology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 5 Hui Xian Medical Center, Hui Xian Medical Center, 999078 - Macao/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2171

Background

Copy number alterations in cyclin D1 (CCND1) relevant to malignant biological behavior exist in solid tumors, including head and neck squamous cell cancer (HNSCC). The prevalence and utility of CCND1 amplification as a biomarker for the clinical response to immune checkpoint inhibitors (ICIs) therapy is unknown.

Methods

This was a three-cohort pooled study, 6904 samples from 6540 patients from the Geneplus Insitute, 10562 samples from the TCGA and 10614 samples from the MSKCC were statistically analyzed. Next-generation sequencing assays were performed in tumor samples at the Geneplus Institute. Genomic, transcriptomic, and clinical data were obtained from TCGA and MSKCC. Comprehensive profiling was performed to determine the prevalence of CCND1 amplification and their correlation with the prognosis and the response to ICIs. Assessment of the CCND1 amplification frequency, overall survival (OS), gene set enrichment analysis (GSEA) and immune profile in solid tumors.

Results

In HNSCC, 7 cases (25.00%) were identified CCND1 amplification in the Chinese cohort, 120 cases (23.21%) in the TCGA cohort, and 5 cases (9.43%) in the MSKCC cohort. Survival analysis showed that CCND1 amplification was an independent prognostic factor for poor outcome in HNSCC as well as for pan-cancer in the TCGA and MSKCC populations. Furthermore, in the MSKCC cohort, patients receiving ICIs with CCND1 amplification had a shorter OS compared with neutral patients (HR, 1.63; 95%CI, 1.09–2.43; median OS, 11.0m vs. 18.0m; P = .0024), especial in the high-TMB subgroup (HR, 2.82; 95%CI, 1.11–7.20; median OS, 10.0m vs. 41.0m; P = .0003). Comparing the transcriptome between amplification and neutral groups in six solid tumors from the TCGA cohort showed various degrees of immunosuppression in the tumor microenvironment (TME), especially in HNSCC. The GSEA suggested that multiple aggressive, immunosuppressive and angiogenic hallmarks correlate with CCND1 amplification in HNSCC.

Conclusions

These findings indicate that CCND1 amplification may be a key point related to immunosuppression in TME and multiple malignancy hallmarks, and it hinders not only the natural host immune responses but also the efficacy of ICIs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Chuan Ben Chen.

Funding

Ministry of Health P.R.China (Grant No. WKJ2016-2-33).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.